| dc.contributor.author | Bayram, Nurun Nisa | |
| dc.contributor.author | Isoglu, Sevil Dincer | |
| dc.contributor.author | Baran, Yael | |
| dc.contributor.author | Ulu, Gizem Tugce | |
| dc.date.accessioned | 2022-02-16T11:32:17Z | |
| dc.date.available | 2022-02-16T11:32:17Z | |
| dc.date.issued | 2021 | en_US |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.uri | https //doi.org/10.1016/j.annonc.2021.08.309 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12573/1150 | |
| dc.description | Research grants from the Scientific and Technological Research Council of Turkey, "Development of Breast Cancer Targeted, More Stable, IV Double-Moiety pHSensitive, Drug-Conjugated, Multifunctional Micelle-Based Nanocarriers and Investigation of Their in vitro Efficiency", Project Number: 116R057. | en_US |
| dc.description.abstract | Advantage of co-culture strategy for targeted cancer treatment and in vitro studies | en_US |
| dc.description.sponsorship | Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) 116R057 | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | ELSEVIERRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS | en_US |
| dc.relation.isversionof | 10.1016/j.annonc.2021.08.309 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Advantage of co-culture strategy for targeted cancer treatment and in vitro studies | en_US |
| dc.type | article | en_US |
| dc.contributor.department | AGÜ, Mühendislik Fakültesi, Malzeme Bilimi ve Nanoteknoloji Mühendisliği Bölümü | en_US |
| dc.contributor.institutionauthor | Bayram, Nurun Nisa | |
| dc.contributor.institutionauthor | Isoglu, Sevil Dincer | |
| dc.identifier.volume | Volume 32 Page S 370-S 370 Supplement 5 Meeting Abstract 31P | en_US |
| dc.relation.journal | ANNALS OF ONCOLOGY | en_US |
| dc.relation.tubitak | 116R057 | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
